AsiaBerlin Summit 2025

24–28 Nov 2025 | Berlin, Germany

Lei Sun

Board chairman

NewLab Biotechnology (Chengdu) Co., Ltd

Chengdu, China

8 profile visitsAttendee

My organisation

NewLab Biotechnology has accumulated experience in nearly 400 preclinical translational research projects of innovative pharmaceuticals and medical devices, having helped partners secure over 30 clinical trial approvals in China, 2 in the US, and more than 5 marketing authorizations, while leading or participating in research projects with a total funding scale of tens of millions. We are also an innovation accelerator specializing in the cardiovascular field, integrating "medical-engineering-R&D + research-production-investment" models, with a proven track record of spearheading the regulatory approval and commercialization of structural heart products including TAVR.
Read more

About me

Mr Lei Sun is the Founder and Chairman of NewLab Biotechnology (Chengdu) Co., Ltd., a young entrepreneur and an innovation driver in the biopharmaceutical field. He founded NewLab Bio in 2022, anchoring the core positioning of "the strongest innovation engine for pharmaceutical and medical device research, and the most trusted R&D external brain for customers", and leading the company to build a high-standard preclinical R&D service platform for pharmaceuticals and medical devices from scratch.

Leveraging the distinctive advantage of deep integration between these two platforms, we broke through traditional R&D boundaries using an "drug-device synergy" approach to precisely address unmet clinical needs and pain points.